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Senescence is increasingly recognized as a critical feature of mammalian cells to suppress tumorigenesis,
acting together with cell death programs.Whether senescence, like programmed cell death, can be exploited
therapeutically has been unclear. Pandolfi and coworkers now propose that PTEN-loss-induced cellular
senescence (PICS) may be triggered in vivo for therapy.Originally, cellular senescence was de-
scribed as a state of cell-cycle arrest
occurring in response to prolonged
culturing of untransformed human cells
in vitro. In addition to the progressive
shortening of telomeres, other stress
signals, owing to inadequate culturing
conditions, can elicit this premature form
of arrest. Senescence can be triggered
also by other alterations, like the expres-
sion of an oncogene that is activated by
mutation. The associated cessation of
cell proliferation is largely irreversible:
although cells can be senescent for long
periods of time without loss of metabolic
activity, they can re-enter the cell cycle
only upon disruption of specific signaling
cascades (Campisi, 2005). Senescence
is often associated with the secretion of
dozens of factors that mediate communi-
cation between senescent cells and their
microenvironment (Kuilman and Peeper,
2009). The execution of the senescence
program relies on the activation of several
tumor suppressor routes, most if not all of
which are frequently altered in human
cancers.
Since 2005, evidence demonstrating
that cellular senescence corresponds to
a common phenomenon bearing strong
physiological relevance has accumulated
rapidly. Senescence biomarkers have
been identified in a number of human
lesions, includingmelanocytic nevi (moles),
neurofibromas, and prostate intraepithelial
neoplasia (PIN) (Collado and Serrano,
2010). These observations are corrobo-
rated in an increasing series of mouse
models. For example, expression of the
cancer-derived BRAFV600E protein kinase
in the melanocytic compartment triggers
lesions closely resembling human nevi.
Only in the presence of a second mutation
theymassivelyprogress tomalignancyand
form metastasizing melanomas (Dankortetal., 2009).Othermodelshavehighlighted
that not only oncogene activation but
also loss of tumor-suppressor genes can
activate a senescence program in vivo.
The activation of senescence by loss
of tumor-suppressor genes can be exem-
plified by PTEN, which is among the
most commonly mutated tumor suppres-
sors in human cancer. PTEN encodes a
phosphatase catalyzing the conversion
of the membrane lipid PIP3 to the
PI3K substrate PIP2, fueling downstream
signaling cascades, including the AKT
pathway. PTEN is often mutated in pros-
tate cancer, the most frequently diag-
nosed cancer in men. Peculiarly, whereas
loss of a single PTEN allele acts mitogeni-
cally, loss of both alleles instead sets
in motion a senescence program, in a
p53-dependent fashion (Chen et al.,
2005). It thus suppresses prostate cancer,
with PTEN dosage inversely correlating
with disease progression (Trotman et al.,
2003).
The powerful tumor-suppressing role of
senescence in vivo prompts the question
as to whether its (re-)activation in tumors
would be a realistic option for cancer
therapy. Similarly, induction of apoptosis
in tumor cells, whether by chemothera-
peutics or signaling molecules, can be
successfully utilized clinically. Studying
PTEN-loss-induced cellular senescence
(PICS) in detail, Pandolfi and coworkers
now propose that prosenescence ther-
apy, too, may be feasible for blocking
tumor progression, in particular prostate
cancers driven by PTEN loss (Alimonti
et al., 2010). Given that most prostate
tumors have lost one allele of PTEN, the
authors argue that its haploinsufficient
nature renders prostate tumors amenable
to temporary pharmacological inhibition
of the protein that is expressed from the
remaining allele.Cancer Cell 1The investigators compared PICS
to OIS (oncogene-induced senescence)
in vitro. Typically, the cell-cycle arrest of
OIS is preceded by a brief period of hyper-
proliferation. At least for some activated
oncogenes, this is accompanied by hy-
perreplication stress and a DNA damage
response (DDR). Upon loss of Pten,
mouse embryo fibroblasts (MEFs) activate
p53 and its downstreameffectors p21 and
PAI-1. The authors noted that, in contrast
to OIS, PICS kicked in soon after the loss
of PTEN, giving rise to increased SA-b-
Galactosidase activity (as a measure of
senescence) and cessation of prolifera-
tion. Featuresof thesenescence response
were seen also when Pten was deleted in
aphidicolin-arrested cells, indicating that
PICS does not rely on DNA replication. In
contrast to OIS, MEFs undergoing PICS
exited the cell cycle without overt signs
of a DDR. Correspondingly, PIN lesions
in mice displayed increased SA-b-galac-
tosidase activity yet lacked g-H2AX foci,
a marker for DNA breaks.
The uncoupling of PICS from DDR acti-
vation prompted the authors to consider
the possibility of activating PICS in early
tumors, in an effort to prevent them
from progressing to full malignancy. The
concept of activating senescence in early
tumors may sound generally appealing
(particularly for those tumors that are
highly resistant to induction of death).
However, it is questionable whether this
should be a therapeutic aim for lesions
that undergo OIS, given that this may
be accompanied by DNA damage and
subsequent outgrowth of mutated cells.
For PICS, Alimonti et al. reasoned, this
is different because in contrast to OIS,
it does not involve proliferation nor
mounting a DDR.
When Pten-heterozygous, but not WT,
MEFs were exposed to VO-OHpic, an7, March 16, 2010 ª2010 Elsevier Inc. 219
Figure 1. Pharmacologic Induction of PICS
Loss of both gene copies (‘‘no dose’’) of PTEN sets in motion a senescence
program, ‘‘PICS,’’ in a p53- and mTOR-dependent fashion. It occurs in the
absence of a DNA damage response and can be established also in already
arrested cells. Also overexpression of PTEN (‘‘high dose’’), or inactivation of
PI3K, can cause senescence. Cells with a ‘‘low dose’’ (30%–50%of the normal
dose in WT cells) can be forced to enter senescence upon pharmacologic
inhibition of PTEN.
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PTEN, a considerable fraction
increased SA-b-galactosi-
dase activity and slowed
down proliferation. Homozy-
gous Pten-deficient cells, of
which many are already sen-
escent, failed to show this
response, indicating that the
impact of the drug occurs as
a function of PTEN levels.
Also the tumorigenic capacity
of mouse xenografts from
a human prostate carcinoma
cell line (MDA PCa-2b), ex-
pressing low quantities of
PTEN, was decreased upon
VO-OHpic treatment. Similar
to the in vitro settings, the
proliferative activity of the
cancer cells dropped sub-
stantially, which was accom-
panied by an increase in the
number of SA-b-galactosi-
dase-positive cells.
Although we do not yet
know how commonly, se-nescence can be triggered in tumors
upon chemotherapy. Similarly, reactiva-
tion of p53 can elicit not only apoptosis
but also senescence in vivo (Sharpless
and DePinho, 2007). This observation
is consistent with the prevailing model
that cancer proliferation and survival
rely on a set of ‘‘driver’’ genes: activated
oncogenes and inactivated tumor-
suppressor genes. Instead, the paper
by Alimonti et al. argues that, at
least within the context of partial PTEN
deficiency, (further) tumor-suppressor
inactivation can suppress, rather than
drive, tumorigenesis. Because it was
shown previously that ectopic expres-
sion of PTEN or suppression of PI3K
also causes senescence (Courtois-Cox
et al., 2006), the current observations
suggest that the PI3K/PTEN pathway
requires delicate fine-tuning in order to
be compatible with cell proliferation:220 Cancer Cell 17, March 16, 2010 ª2010 Etoo little or too much may act cytostati-
cally.
Is clinical extrapolation of the current
findings, ‘‘prosenescence therapy’’ as the
authors put forward, now within reach?
For this to be feasible, several issues
need to be investigated further. For
example, what is the effect of PTEN inhibi-
tion in different genetic contexts? It is
shown that inactivation of p53 or mTOR
abrogates PICS; it is conceivable that
other (epi)genetic alterations also affect
the outcomeofPTEN inhibition. In addition,
it appears that targeting PTEN would be
beneficial only within a narrow window of
its expression level (Figure 1), which may
fluctuate resulting from tumor heteroge-
neity. And although two-thirds of prostate
tumors suffer from heterozygous PTEN
allelic loss, other mechanisms contribute
to loss of PTEN expression in advanced
prostate cancer (Whang et al., 1998).lsevier Inc.Before prosenescence ther-
apy becomes a realistic goal,
we need to find the answers
to these and other clinically
oriented questions. This not-
withstanding, the findings by
Alimonti et al. are food for
thought because theyhighlight
one out of several vulnerabil-
ities of cancer cells, represent-
ing a feature that cancer
researchers may wish to
further explore for future clin-
ical application.REFERENCES
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